304 related articles for article (PubMed ID: 22136068)
1. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM
Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
Lee CY; Chang HM; Kunin CM; Lee SS; Chen YS; Tsai HC
BMC Infect Dis; 2017 Apr; 17(1):261. PubMed ID: 28399808
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
Giaquinto C; Anabwani G; Feiterna-Sperling C; Nuttall J; Mompati K; Königs C; Mensa FJ; Sabo JP; Yong CL; MacGregor TR; Nguyen T; Quinson AM
Pediatr Infect Dis J; 2014 Jul; 33(7):e173-9. PubMed ID: 24378938
[TBL] [Abstract][Full Text] [Related]
6. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Heil EL; Corbett AH
Expert Opin Pharmacother; 2011 Dec; 12(17):2713-8. PubMed ID: 22035406
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine extended-release for the treatment of HIV-1 infection.
Bogner JR
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):21-30. PubMed ID: 22149611
[TBL] [Abstract][Full Text] [Related]
9. Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.
Bhatti L; Gladstein J
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):369-73. PubMed ID: 22930796
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L;
Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
Parienti JJ; Peytavin G
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):495-503. PubMed ID: 21417819
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
[TBL] [Abstract][Full Text] [Related]
13. Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
Lee YC; Lin SW; Chen MY; Chang SY; Kuo CH; Sheng WH; Hsieh SM; Sun HY; Chang HY; Wu MR; Liu WC; Wu PY; Yang SP; Zhang JY; Su YC; Luo YZ; Hung CC; Chang SC
PLoS One; 2015; 10(10):e0140574. PubMed ID: 26465325
[TBL] [Abstract][Full Text] [Related]
14. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
15. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
[TBL] [Abstract][Full Text] [Related]
17. Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
Stephan C; León W
HIV Med; 2014 Feb; 15(2):124-8. PubMed ID: 24112515
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
Lepik KJ; Yip B; McGovern RA; Ding E; Nohpal A; Watson BE; Toy J; Akagi L; Harrigan PR; Moore DM; Hogg RS; Montaner JS; Barrios R
Antivir Ther; 2015; 20(7):721-30. PubMed ID: 25960569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
